Top Markets
#1 Nesa Nesa +468.43%
#2 Prom Prom +36.57%
#3 MetaDAO MetaDAO +29.39%
#4 Bedrock Bedrock +16.07%
#5 Pons Pons +14.41%
#6 Stacks Stacks +11.18%
#7 Ontology Gas Ontology Gas +10.39%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +10.09%
#9 dogwifhat dogwifhat +9.89%
#10 Tornado Cash Tornado Cash +9.33%
Coin of the day
Nesa Nesa
Settings
Language
ENGLISH
Currency
USD
Theme
Celltrion, Inc. Celltrion, Inc.

Celltrion, Inc.

068270
Rank in Stocks #830
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Share Price
$132.08
Market Cap
$30.29B
Change (1 day)
-1.55%
Change (1 year)
10.60%
Country
KR
Trade Celltrion, Inc. (068270)

Category

Healthcare
Dividend history for Celltrion, Inc. (068270)
Celltrion, Inc. (stock symbol: 068270) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Celltrion, Inc. (068270) from 2026 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
Not enough data for the provided dates.
List of all dividend payments
Year Dividend Change
Not enough data for the provided dates.
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH